Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0G9WP
|
||||
| Former ID |
DNC009637
|
||||
| Drug Name |
5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H11NO
|
||||
| Canonical SMILES |
C1CC(=O)C2=C1C=C(C=C2)C3=CN=CC=C3
|
||||
| InChI |
1S/C14H11NO/c16-14-6-4-11-8-10(3-5-13(11)14)12-2-1-7-15-9-12/h1-3,5,7-9H,4,6H2
|
||||
| InChIKey |
QNSOPUXDEXJMIY-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cytochrome P450 11B1, mitochondrial | Target Info | Inhibitor | [1] | |
| Cytochrome P450 19 | Target Info | Inhibitor | [1] | ||
| BioCyc Pathway | Superpathway of steroid hormone biosynthesis | ||||
| Glucocorticoid biosynthesis | |||||
| Mineralocorticoid biosynthesisPWY-7305:Superpathway of steroid hormone biosynthesis | |||||
| Estradiol biosynthesis II | |||||
| Estradiol biosynthesis I | |||||
| KEGG Pathway | Steroid hormone biosynthesis | ||||
| Metabolic pathwayshsa00140:Steroid hormone biosynthesis | |||||
| Metabolic pathways | |||||
| Ovarian steroidogenesis | |||||
| NetPath Pathway | FSH Signaling Pathway | ||||
| PANTHER Pathway | Androgen/estrogene/progesterone biosynthesis | ||||
| PathWhiz Pathway | SteroidogenesisPW000045:Androgen and Estrogen Metabolism | ||||
| Reactome | Glucocorticoid biosynthesis | ||||
| Endogenous sterolsR-HSA-211976:Endogenous sterols | |||||
| WikiPathways | Metapathway biotransformation | ||||
| Oxidation by Cytochrome P450 | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| Corticotropin-releasing hormoneWP702:Metapathway biotransformation | |||||
| Tryptophan metabolism | |||||
| Ovarian Infertility Genes | |||||
| FSH signaling pathway | |||||
| Integrated Breast Cancer Pathway | |||||
| Phase 1 - Functionalization of compounds | |||||
| References | |||||
| REF 1 | J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.